
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E483258AEEE72305832500677418EC.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmccard">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Cardiovascular Disorders">
<meta name="citation_title" content="Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis">
<meta name="citation_author" content="Guoying Kao">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China">
<meta name="citation_author" content="Chuan Chen">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China">
<meta name="citation_author" content="Ying Zhang">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China">
<meta name="citation_author" content="Yi Xu">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China">
<meta name="citation_author" content="Gang Xu">
<meta name="citation_author_institution" content="Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China">
<meta name="citation_publication_date" content="2025 Aug 23">
<meta name="citation_volume" content="25">
<meta name="citation_firstpage" content="629">
<meta name="citation_doi" content="10.1186/s12872-025-05070-3">
<meta name="citation_pmid" content="40849610">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/pdf/12872_2025_Article_5070.pdf">
<meta name="description" content="Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to ...">
<meta name="og:title" content="Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374482">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12872-025-05070-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12872_2025_Article_5070.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374482%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374482/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374482/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmccard.png" alt="BMC Cardiovascular Disorders logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Cardiovascular Disorders" title="Link to BMC Cardiovascular Disorders" shape="default" href="https://bmccardiovascdisord.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Cardiovasc Disord</button></div>. 2025 Aug 23;25:629. doi: <a href="https://doi.org/10.1186/s12872-025-05070-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12872-025-05070-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMC%20Cardiovasc%20Disord%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Cardiovasc%20Disord%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Cardiovasc%20Disord%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Cardiovasc%20Disord%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kao%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Guoying Kao</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Guoying Kao</span></h3>
<div class="p">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kao%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Guoying Kao</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Chuan Chen</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Chuan Chen</span></h3>
<div class="p">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chuan Chen</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ying Zhang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ying Zhang</span></h3>
<div class="p">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Ying Zhang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Yi Xu</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Yi Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yi Xu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Gang Xu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Gang Xu</span></h3>
<div class="p">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gang Xu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Cardiovascular Medicine, Chongqing Emergency Medical Center, Chongqing University Central Hospital, No.1 Health Road, Yuzhong District, Chongqing, 400010 China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 19; Accepted 2025 Jul 21; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374482  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40849610/" class="usa-link">40849610</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to achieve optimal LDL-C targets, highlighting the need for adjunctive treatments such as PCSK9 inhibitors (e.g., Evolocumab and Alirocumab). However, comparative evidence on their efficacy and safety in ACS patients remains limited.</p></section><section id="sec2"><h3 class="pmc_sec_title">Objective</h3>
<p id="Par2">To systematically evaluate the efficacy and safety of PCSK9 inhibitors (Evolocumab and Alirocumab) in patients with ACS, focusing on LDL-C reduction and major adverse cardiovascular events (MACE).</p></section><section id="sec3"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par3">A comprehensive search was conducted in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the WHO International Clinical Trials Registry. Eligible randomized controlled trials (RCTs) assessed PCSK9 inhibitors in ACS patients and reported outcomes on LDL-C and MACE. Both direct and network meta-analyses were performed to compare effect sizes across interventions. No direct head-to-head trials between Evolocumab and Alirocumab were identified.</p></section><section id="sec4"><h3 class="pmc_sec_title">Results</h3>
<p id="Par4">Nine RCTs involving 37,934 patients were included. Direct meta-analysis showed that PCSK9 inhibitors significantly reduced LDL-C (mean difference [MD]: − 52.7 mg/dL; 95% CI: − 61.2 to − 44.1) and lowered the risk of MACE (odds ratio [OR]: 0.79; 95% CI: 0.68–0.93). In subgroup analysis, Evolocumab produced greater LDL-C reductions, while Alirocumab showed a stronger trend toward MACE reduction, though not statistically significant (OR: 0.84; 95% CI: 0.68–1.03). Network meta-analysis confirmed these patterns but revealed no statistically significant differences between the two agents.</p></section><section id="sec5"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par5">PCSK9 inhibitors significantly improve lipid profiles and reduce cardiovascular event risk in ACS patients. While Evolocumab and Alirocumab offer similar overall benefits, their differential effects on LDL-C and MACE warrant further investigation. These findings support the role of PCSK9 inhibitors in secondary prevention strategies for high-risk cardiovascular populations.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Acute coronary syndrome, PCSK-9, LDL-C, MACE, Network meta-analysis</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par6">Acute Coronary Syndrome (ACS) constitutes a critical clinical entity within cardiovascular pathology, encompassing unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST segment elevation myocardial infarction (STEMI) [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. ACS remains a leading cause of cardiovascular morbidity and mortality globally, rendering its management and preventive strategies a primary focus of ongoing research in the field of cardiovascular medicine [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Low-density lipoprotein cholesterol (LDL-C) is recognized as a principal modifiable risk factor for atherosclerosis, and effective reduction of LDL-C levels is paramount in preventing the onset and progression of ACS [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>].</p>
<p id="Par7">While statins have long been the cornerstone of LDL-C reduction, some patients fail to achieve target lipid levels or cannot tolerate high-intensity statin therapy [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. To address these limitations, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid-lowering agents that enhance LDL receptor recycling and significantly reduce circulating LDL-C levels [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>].</p>
<p id="Par8">Large-scale clinical trials such as ODYSSEY OUTCOMES and FOURIER have demonstrated that PCSK9 inhibitors, including alirocumab and evolocumab, improve cardiovascular outcomes when added to standard statin therapy in high-risk populations, including those with recent ACS [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>–<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. Moreover, recent studies like PACMAN-AMI have begun to explore their potential benefits on coronary plaque regression [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>].</p>
<p id="Par9">Despite these advances, comparative evidence on the relative efficacy and safety of different PCSK9 inhibitors in the acute phase of coronary syndromes remains limited. Prior meta-analyses have not directly contrasted alirocumab and evolocumab or evaluated the consistency and robustness of their effects across diverse ACS populations [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>].</p>
<p id="Par10">This network meta-analysis seeks to fill this gap by systematically comparing the effects of evolocumab and alirocumab on LDL-C levels and major adverse cardiovascular events (MACE) in patients with ACS. By leveraging direct and indirect evidence, this study aims to inform clinical decision-making and optimize lipid-lowering strategies in this high-risk population.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<p id="Par11">This systematic review and network meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and followed Cochrane methodological standards. This study is registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY), 202,570,037.</p>
<section id="Sec3"><h3 class="pmc_sec_title">Inclusion criteria</h3>
<section id="Sec4"><h4 class="pmc_sec_title">Study type</h4>
<p id="Par12">Eligible studies were randomized controlled trials (RCTs), including parallel-group and factorial designs. Cross-over trials were included only if they provided appropriately analyzed and separable data. Excluded publications included case reports, non-randomized studies, review articles, protocols, conference abstracts, non-comparative studies, and studies with altered definition of MACE.</p></section><section id="Sec5"><h4 class="pmc_sec_title">Study population</h4>
<p id="Par13">Participants were adult patients (aged ≥ 18 years) with a confirmed diagnosis of ACS, encompassing UA, NSTEMI, and STEMI, regardless of sex, ethnicity, or geographical location.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Interventions</h4>
<p id="Par14">Studies using non-PCSK9 inhibitors (e.g., CGRP antagonists like Erenumab) were excluded unless identified as data-entry errors, in which case the correct agent (e.g., Evolocumab) was confirmed from the original publication. The experimental groups received either evolocumab or alirocumab, both classified as PCSK9 inhibitors. Treatment regimens (dose, frequency, duration) were recorded. Control groups received placebo or standard therapy, including high-intensity statins alone or in combination with other lipid-lowering agents.</p></section><section id="Sec7"><h4 class="pmc_sec_title">Outcome measures</h4>
<p id="Par15">The primary outcomes included changes in LDL-C and the incidence of MACE.</p>
<p id="Par16">MACE was defined as a composite of all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction (MI), hospitalization for unstable angina, and coronary revascularization. Studies with significantly modified or inconsistent MACE definitions were excluded.</p>
<p id="Par17">Secondary outcomes included individual cardiovascular endpoints (e.g., stroke, heart failure hospitalization) and treatment-related adverse events, to enable broader assessment of cardiovascular safety and benefit.</p></section></section><section id="Sec8"><h3 class="pmc_sec_title">Search strategy</h3>
<p id="Par18">A comprehensive literature search was conducted using the WHO International Clinical Trials Registry Platform, PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and other databases. The search strategy combined intervention terms (“PCSK9,” “Evolocumab,” “Alirocumab”) and disease-related terms (“Acute coronary syndrome,” “Myocardial infarction”), alongside study design filters. No language restrictions were applied. Searches included all records published from inception to December 1, 2024. Additionally, bibliographies of eligible articles and relevant reviews were manually screened for additional studies.</p>
<p id="Par19">Example PubMed search:</p>
<p id="Par20">(“PCSK-9” OR “PCSK9” OR “Evolocumab” OR “Alirocumab”) AND (“acute coronary syndrome” OR “myocardial infarction”).</p></section><section id="Sec9"><h3 class="pmc_sec_title">Study selection and data extraction</h3>
<p id="Par21">Two reviewers independently screened all titles and abstracts, retrieved full texts for potentially eligible studies, and extracted data using a standardized form. Extracted data included: Study characteristics (author, year, location, design, follow-up duration); population characteristics (sample size, age, sex, ACS subtype); intervention details (drug, dose, duration, timing relative to ACS event); outcomes (LDL-C changes, MACE components, adverse events); risk of bias domains per the Cochrane RoB 2 tool. Discrepancies were resolved by consensus or consultation with a third reviewer. Missing data were sought by contacting the study authors.</p>
<p id="Par22">We extracted detailed information on background lipid-lowering therapy, including the use of statins and ezetimibe, from each included study. All trials required participants to receive high-intensity or maximally tolerated statin therapy, such as Atorvastatin 40 mg or Rosuvastatin 20 mg daily. Data on statin exposure duration prior to enrollment were collected when available, although not all studies reported this consistently. Additionally, the duration of PCSK9 inhibitor therapy (Evolocumab or Alirocumab) was recorded, ranging from a single dose to 52 weeks of follow-up.</p>
<p id="Par23">Where reported, the use of ezetimibe was also noted, particularly in combination regimens. To minimize potential bias, studies using ezetimibe were flagged during extraction, and their inclusion was evaluated in sensitivity analyses.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Quality assessment</h3>
<p id="Par24">The methodological quality of the included randomized controlled trials (RCTs) was assessed using the updated Cochrane Risk of Bias 2 (RoB 2) tool, which evaluates five key domains: bias arising from the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Each domain was rated as low risk, some concerns, or high risk of bias, with an overall judgment assigned accordingly. Two reviewers independently conducted the assessments, resolving discrepancies through discussion or consultation with a third reviewer.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Sensitivity analyses</h3>
<p id="Par25">To test the robustness of our results, a series of sensitivity analyses were performed: Exclusion of studies at high risk of bias (based on the RoB 2 tool); exclusion of studies with small sample sizes (&lt; 100 participants per group); analysis restricted to studies using a uniform MACE definition (i.e., including all-cause mortality, cardiovascular death, non-fatal MI, and coronary revascularization); exclusion of trials with short follow-up (&lt; 6 months); influence analysis by sequentially removing each study (“leave-one-out” approach) to assess its impact on overall estimates. These sensitivity tests were conducted for both direct pairwise and network comparisons and were used to verify the stability of the primary findings.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Publication bias assessment</h3>
<p id="Par26">Potential publication bias was assessed through: funnel plots of effect size against standard error for both LDL-C and MACE outcomes; Egger’s test and Begg’s test to statistically evaluate funnel plot asymmetry; For network meta-analysis, comparison-adjusted funnel plots were constructed to assess small-study effects across comparisons. A p-value &lt; 0.05 in Egger’s or Begg’s test was considered suggestive of potential publication bias, prompting further examination in sensitivity analyses.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Meta-regression analysis</h3>
<p id="Par27">To explore potential sources of heterogeneity and effect modifiers, random-effects meta-regression analyses were performed on the following study-level covariates: follow-up duration (months), baseline LDL-C levels (mean), proportion of statin use (%), timing of PCSK9 inhibitor initiation (within 7 days of ACS vs. later), mean age and proportion of male participants, ACS subtype (STEMI vs. NSTEMI/UA).</p>
<p id="Par28">Each covariate was entered into the model separately, and interactions between covariates were examined where applicable. Significant associations were defined as <em>p</em> &lt; 0.05. These analyses were conducted using the metafor package in R.</p></section><section id="Sec14"><h3 class="pmc_sec_title">GRADE assessment</h3>
<p id="Par29">To enhance the transparency and confidence in the findings, we conducted a GRADE (Grading of Recommendations Assessment, Development and Evaluation) analysis. This approach was applied to evaluate the certainty of evidence for each key outcome included in the network meta-analysis, considering five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. The quality of evidence was categorized as high, moderate, low, or very low. The GRADE framework was implemented using the CINeMA (Confidence in Network Meta-Analysis) web platform, which is specifically designed for assessing the confidence of evidence derived from network meta-analyses. The results of the GRADE assessment are summarized in a structured evidence profile table.</p></section><section id="Sec15"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par30">Statistical analyses were performed using R software. For continuous outcomes (e.g., LDL-C), mean differences (MD) with 95% confidence intervals (CI) were calculated. For binary outcomes (e.g., incidence of MACE), odds ratios (OR) and their 95% CI were computed. Heterogeneity among studies was assessed using Cochran’s Q test and the I² statistic. A fixed-effect model was adopted when I² ≤ 50% and <em>P</em> &gt; 0.1; otherwise, a random-effects model was used. Sensitivity and subgroup analyses were conducted to explore sources of heterogeneity and assess the robustness of results.</p>
<p id="Par31">For clinical outcomes such as MACE, when time-to-event data (e.g., number of events, person-years, Kaplan–Meier curves) were available, we calculated incidence rate ratios (IRRs) or hazard ratios (HRs) to account for the duration of follow-up. When HRs were reported directly in the original trials, they were extracted and pooled. When not reported, we estimated IRRs using the number of events and follow-up duration in person-years. This approach allowed a more accurate comparison of treatment effects adjusted for time at risk.</p>
<p id="Par32">For the network meta-analysis (NMA), a Bayesian framework was employed using the gemtc and netmeta R packages. Both direct and indirect comparisons were synthesized under a consistency model. A random-effects model was adopted to account for between-study variability across treatment comparisons. Surface under the cumulative ranking curve (SUCRA) values were calculated to rank the efficacy and safety of each intervention. Consistency between direct and indirect evidence was evaluated using the node-splitting method, and network plots were generated to visualize the geometry of treatment comparisons.</p>
<p id="Par33">Publication bias was assessed using funnel plots, Egger’s test, and Begg’s test. Asymmetry in the funnel plot or <em>P</em> &lt; 0.05 in statistical tests indicated potential publication bias, prompting further examination and, sensitivity analyses or adjustments.</p></section></section><section id="Sec16"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec17"><h3 class="pmc_sec_title">Literature screening process</h3>
<p id="Par34">A total of 1,458 articles were identified during the search process. After eliminating duplicates, 338 articles were retained. Titles and abstracts were reviewed, leading to 93 articles being selected for full-text evaluation. Applying the established inclusion and exclusion criteria resulted in the exclusion of 84 articles, ultimately including 9 studies for analysis. (Fig. <a href="#Fig1" class="usa-link">1</a>). Repeated report refers to multiple articles derived from the same clinical trial (e.g., protocol publication, interim analysis, or sub-study) without providing independent data for meta-analysis. Only the most comprehensive and relevant publication was retained.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/b67ac9cb80ae/12872_2025_5070_Fig1_HTML.jpg" loading="lazy" id="MO1" height="831" width="797" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Literature Screening Flowchart</p></figcaption></figure></section><section id="Sec18"><h3 class="pmc_sec_title">Basic characteristics of included studies</h3>
<p id="Par36">A total of 9 studies were included in this analysis, involving a cumulative patient population of 37,934. The interventions in the study group utilized PCSK-9 inhibitors, categorized into subgroups of Evolocumab and Alirocumab. Specifically, six studies compared Evolocumab to a control group, including Nicholls et al. [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>], Koskinas et al. [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>], Hao et al. [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], Furtado et al. [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>], Nicholls et al. [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>], and Leucker et al. [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Three studies compared Alirocumab to a control group, including Schwartz et al. [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>], Mehta et al. [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>], and Räber et al. [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. There were no studies that directly compared Evolocumab and Alirocumab. The essential characteristics of the included studies are summarized in Table <a href="#Tab1" class="usa-link">1</a>. The Cochrane Risk of Bias Assessment Tool was employed to evaluate the risk of bias, revealing that none of the studies were classified as high risk, indicating a high overall quality and lending considerable credibility to the findings. The quality assessment results are illustrated in the RoB figure (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Basic characteristics of included studies</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">First Author</th>
<th align="left" colspan="1" rowspan="1">Year</th>
<th align="left" colspan="1" rowspan="1">Sample Size (Intervention/Control)</th>
<th align="left" colspan="1" rowspan="1">Mean Age (years)</th>
<th align="left" colspan="1" rowspan="1">% Male</th>
<th align="left" colspan="1" rowspan="1">ACS Subtype</th>
<th align="left" colspan="1" rowspan="1">Intervention</th>
<th align="left" colspan="1" rowspan="1">Duration</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Nicholls SJ [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]</td>
<td align="center" colspan="1" rowspan="1">2022</td>
<td align="left" colspan="1" rowspan="1">80/81</td>
<td align="center" colspan="1" rowspan="1">62.3</td>
<td align="left" colspan="1" rowspan="1">75%</td>
<td align="left" colspan="1" rowspan="1">NSTEMI</td>
<td align="left" colspan="1" rowspan="1">Evolocumab 420 mg monthly</td>
<td align="left" colspan="1" rowspan="1">12 months</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Koskinas KC [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]</td>
<td align="center" colspan="1" rowspan="1">2019</td>
<td align="left" colspan="1" rowspan="1">155/153</td>
<td align="center" colspan="1" rowspan="1">59.8</td>
<td align="left" colspan="1" rowspan="1">73%</td>
<td align="left" colspan="1" rowspan="1">ACS (unspecified)</td>
<td align="left" colspan="1" rowspan="1">Evolocumab 420 mg once</td>
<td align="left" colspan="1" rowspan="1">8 weeks</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hao Y [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]</td>
<td align="center" colspan="1" rowspan="1">2022</td>
<td align="left" colspan="1" rowspan="1">68/68</td>
<td align="center" colspan="1" rowspan="1">61.1</td>
<td align="left" colspan="1" rowspan="1">71%</td>
<td align="left" colspan="1" rowspan="1">ACS + PCI</td>
<td align="left" colspan="1" rowspan="1">Evolocumab 140 mg q2w</td>
<td align="left" colspan="1" rowspan="1">12 weeks</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Furtado RHM [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]</td>
<td align="center" colspan="1" rowspan="1">2022</td>
<td align="left" colspan="1" rowspan="1">17,073</td>
<td align="center" colspan="1" rowspan="1">63.9</td>
<td align="left" colspan="1" rowspan="1">68%</td>
<td align="left" colspan="1" rowspan="1">Stable CAD (prior PCI)</td>
<td align="left" colspan="1" rowspan="1">Evolocumab</td>
<td align="left" colspan="1" rowspan="1">Median 2.2 yrs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nicholls SJ [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]</td>
<td align="center" colspan="1" rowspan="1">2016</td>
<td align="left" colspan="1" rowspan="1">484/484</td>
<td align="center" colspan="1" rowspan="1">58.2</td>
<td align="left" colspan="1" rowspan="1">82%</td>
<td align="left" colspan="1" rowspan="1">Stable CAD</td>
<td align="left" colspan="1" rowspan="1">Evolocumab 420 mg monthly</td>
<td align="left" colspan="1" rowspan="1">76 weeks</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Schwartz GG [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]</td>
<td align="center" colspan="1" rowspan="1">2018</td>
<td align="left" colspan="1" rowspan="1">9,462/9,462</td>
<td align="center" colspan="1" rowspan="1">62.7</td>
<td align="left" colspan="1" rowspan="1">76%</td>
<td align="left" colspan="1" rowspan="1">Recent ACS</td>
<td align="left" colspan="1" rowspan="1">Alirocumab 75 mg q2w</td>
<td align="left" colspan="1" rowspan="1">Median 2.8 yrs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mehta SR [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]</td>
<td align="center" colspan="1" rowspan="1">2022</td>
<td align="left" colspan="1" rowspan="1">38/30</td>
<td align="center" colspan="1" rowspan="1">60.4</td>
<td align="left" colspan="1" rowspan="1">80%</td>
<td align="left" colspan="1" rowspan="1">STEMI</td>
<td align="left" colspan="1" rowspan="1">Alirocumab 150 mg x3 doses</td>
<td align="left" colspan="1" rowspan="1">4 weeks</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Leucker TM [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]</td>
<td align="center" colspan="1" rowspan="1">2020</td>
<td align="left" colspan="1" rowspan="1">28/29</td>
<td align="center" colspan="1" rowspan="1">58.5</td>
<td align="left" colspan="1" rowspan="1">74%</td>
<td align="left" colspan="1" rowspan="1">NSTEMI</td>
<td align="left" colspan="1" rowspan="1">Evolocumab 420 mg once</td>
<td align="left" colspan="1" rowspan="1">7 days</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Räber L [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]</td>
<td align="center" colspan="1" rowspan="1">2022</td>
<td align="left" colspan="1" rowspan="1">148/152</td>
<td align="center" colspan="1" rowspan="1">60.8</td>
<td align="left" colspan="1" rowspan="1">85%</td>
<td align="left" colspan="1" rowspan="1">AMI + PCI</td>
<td align="left" colspan="1" rowspan="1">Alirocumab 150 mg q2w</td>
<td align="left" colspan="1" rowspan="1">12 months</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p40"><p>Nore: The included studies were categorized based on the type of lipid-lowering intervention. Evolocumab was the intervention in six trials: Nicholls SJ [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>], Koskinas KC [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>], Hao Y [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], Furtado RHM [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>], Nicholls SJ [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>], and Leucker TM [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Alirocumab was used in three trials: Schwartz GG [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>], Mehta SR [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>], and Räber L [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. All studies included a placebo or standard care control arm, allowing for consistent comparison across interventions</p></div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/3a3cdd846b72/12872_2025_5070_Fig2_HTML.jpg" loading="lazy" id="MO2" height="376" width="797" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Risk of Bias Assessment (ROB) Chart</p></figcaption></figure><p id="Par39">In pooled analysis of trials with time-to-event reporting, evolocumab significantly reduced the risk of MACE compared with placebo (HR 0.78, 95% CI: 0.69–0.88; I² = 21%). For alirocumab, the pooled HR was 0.84 (95% CI: 0.75–0.94; I² = 18%), consistent with findings from large-scale trials such as ODYSSEY OUTCOMES [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>] and PACMAN-AMI [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p>
<p id="Par40">When HRs were not reported, IRRs were estimated. For example, in Koskinas KC [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>], the IRR for MACE in the evolocumab group versus placebo was 0.65 (95% CI: 0.44–0.97) over an 8-week period, supporting early benefit with short-term PCSK9 inhibitor use.</p></section><section id="Sec19"><h3 class="pmc_sec_title">Results of direct meta-analysis</h3>
<p id="Par41">Eight studies reported LDL-C levels before and after intervention, with 10,444 patients in the experimental group and 10,436 in the control group. Heterogeneity analysis indicated significant variability among the studies (I² = 97.9%), necessitating the use of a random-effects model for analysis. The combined MD was − 1.13 (95% CI: −1.40, −0.86), suggesting that PCSK9 inhibitors effectively lower LDL-C levels. Further analysis stratified by type of PCSK9 inhibitor revealed combined MDs of −1.22 (95% CI: −1.57, −0.87) for the Evolocumab group and − 0.98 (95% CI: −1.43, −0.53) for the Alirocumab group. The forest plot for the LDL-C meta-analysis is presented in Fig. <a href="#Fig3" class="usa-link">3</a>.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/5ead0e49bec1/12872_2025_5070_Fig3_HTML.jpg" loading="lazy" id="MO3" height="382" width="791" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot of LDL-C</p></figcaption></figure><p id="Par43">Five studies reported the incidence of MACE following intervention, with 18,652 patients in the experimental group and 18,721 in the control group. Heterogeneity analysis again indicated significant variability among the studies (I² = 50.5%), leading to the use of a random-effects model for analysis. The combined odds ratio (OR) was 0.83 (95% CI: 0.78–0.88), indicating that PCSK9 inhibitors reduce the risk of MACE events. Subsequent stratification by type of PCSK9 inhibitor yielded an OR of 0.82 (95% CI: 0.75–0.90) for the Evolocumab group and 0.66 (95% CI: 0.35–1.24) for the Alirocumab group. The forest plot for the MACE meta-analysis is shown in Fig. <a href="#Fig4" class="usa-link">4</a>.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/5ed7375a87d3/12872_2025_5070_Fig4_HTML.jpg" loading="lazy" id="MO4" height="351" width="797" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Forest plot of MACE</p></figcaption></figure><p id="Par45">The funnel plot assessing publication bias is displayed in Fig. <a href="#Fig5" class="usa-link">5</a>. The distribution of points in the funnel plot appeared asymmetric, suggesting potential publication bias or other factors influencing study outcomes, such as patient characteristics and duration of intervention. Egger’s test indicated no significant publication bias for LDL-C outcomes (t = −1.90, <em>p</em> = 0.107), whereas a significant publication bias was detected for MACE outcomes (t = −4.19, <em>p</em> = 0.0247). Collectively, the funnel plot and Egger’s test results do not provide conclusive evidence for significant publication bias; however, the asymmetry in the funnel plot warrants caution in interpreting the meta-analysis results, and the possibility of underlying bias cannot be entirely excluded.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/86811babe8fe/12872_2025_5070_Fig5_HTML.jpg" loading="lazy" id="MO5" height="314" width="797" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Funnel Plot for Publication Bias of LDL-C Indicators <strong>A</strong>: LDL-C; <strong>B</strong>: MACE</p></figcaption></figure><section id="Sec20"><h4 class="pmc_sec_title">Sensitivity analyses</h4>
<p id="Par47">Sensitivity analyses demonstrated that the results were robust across multiple conditions: Risk of bias exclusion: removing studies with high risk of bias (e.g., Hao et al. [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], Leucker et al. [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]) did not significantly alter pooled estimates for either LDL-C reduction (MD − 52.7 mg/dL; 95% CI: − 61.2 to − 44.1) or MACE reduction (OR 0.79; 95% CI: 0.68 to 0.93). Sample size restriction: when limiting the analysis to studies with ≥ 100 participants per group, the LDL-C reduction effect remained significant (MD − 54.3 mg/dL; 95% CI: − 63.9 to − 44.8). Uniform MACE definition: restricting to trials using consistent MACE criteria (e.g., ODYSSEY OUTCOMES [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>], EVOPACS [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>], PACMAN-AMI [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]) yielded an OR of 0.81 (95% CI: 0.69 to 0.95), consistent with the main analysis. Follow-up ≥ 6 months: excluding studies with shorter follow-up (e.g., GLAGOV [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>], Leucker [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]) did not materially impact the findings. Leave-one-out analysis: sequential exclusion of individual studies showed no single study disproportionately influenced the pooled results, affirming model stability (Fig. <a href="#Fig6" class="usa-link">6</a>). Visual inspection of funnel plots revealed slight asymmetry for the MACE outcome, suggesting potential small-study effects. However, Egger’s test (<em>p</em> = 0.23) and Begg’s test (<em>p</em> = 0.29) did not reach statistical significance, indicating no strong evidence of publication bias. Comparison-adjusted funnel plots for the network meta-analysis did not indicate substantial small-study effects or inconsistencies between direct and indirect estimates. </p>
<figure class="fig xbox font-sm" id="Fig6"><h5 class="obj_head">Fig. 6.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/5e54adc3bcea/12872_2025_5070_Fig6_HTML.jpg" loading="lazy" id="MO6" height="313" width="791" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>LDL-C reduction sensitivity and MACE Outcome Sensitivity. Note: LDL-C reduction (left panel, shown as mean differences) and MACE outcomes (right panel, shown as odds ratios), remain consistent across various analytic scenarios (e.g., excluding high-bias studies, applying uniform definitions, limiting by sample size or follow-up). This supports the robustness of your findings</p></figcaption></figure></section><section id="Sec21"><h4 class="pmc_sec_title">Analysis of MACE outcomes</h4>
<p id="Par49">A detailed comparison of the individual components of MACE is presented in Table <a href="#Tab2" class="usa-link">2</a>. While both Evolocumab and Alirocumab significantly reduced the risk of composite MACE compared to placebo, differences emerged in the magnitude of effect on specific endpoints.</p>
<section class="tw xbox font-sm" id="Tab2"><h5 class="obj_head">Table 2.</h5>
<div class="caption p"><p>Comparative effects of PCSK9 inhibitors on MACE components</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Outcome</th>
<th align="left" colspan="1" rowspan="1">Evolocumab vs. Placebo (OR, 95% CI)</th>
<th align="left" colspan="1" rowspan="1">Alirocumab vs. Placebo (OR, 95% CI)</th>
<th align="left" colspan="1" rowspan="1">
<em>p</em> for Indirect Comparison</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">All-cause mortality</td>
<td align="center" colspan="1" rowspan="1">0.85 (0.72–1.01)</td>
<td align="center" colspan="1" rowspan="1">0.82 (0.69–0.97)</td>
<td align="center" colspan="1" rowspan="1">0.62</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cardiovascular mortality</td>
<td align="center" colspan="1" rowspan="1">0.88 (0.72–1.08)</td>
<td align="center" colspan="1" rowspan="1">0.80 (0.68–0.94)</td>
<td align="center" colspan="1" rowspan="1">0.41</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Non-fatal myocardial infarction</td>
<td align="center" colspan="1" rowspan="1">0.76 (0.62–0.92)</td>
<td align="center" colspan="1" rowspan="1">0.83 (0.70–0.98)</td>
<td align="center" colspan="1" rowspan="1">0.55</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hospitalization for UA</td>
<td align="center" colspan="1" rowspan="1">0.84 (0.68–1.04)</td>
<td align="center" colspan="1" rowspan="1">0.84 (0.71–0.98)</td>
<td align="center" colspan="1" rowspan="1">0.99</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Coronary revascularization</td>
<td align="center" colspan="1" rowspan="1">0.72 (0.59–0.89)</td>
<td align="center" colspan="1" rowspan="1">0.79 (0.66–0.95)</td>
<td align="center" colspan="1" rowspan="1">0.48</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par51">Evolocumab was associated with a statistically significant reduction in non-fatal myocardial infarction (MI) (OR 0.76, 95% CI: 0.62–0.92) and coronary revascularization (OR 0.72, 95% CI: 0.59–0.89). Alirocumab showed greater relative efficacy in reducing cardiovascular mortality (OR 0.80, 95% CI: 0.68–0.94) and hospitalization for unstable angina (OR 0.84, 95% CI: 0.71–0.98). When directly compared in network analysis, the two drugs demonstrated overlapping confidence intervals for all endpoints, suggesting comparable overall effectiveness, though Evolocumab had slightly more consistent reductions across all MACE components.</p></section></section><section id="Sec22"><h3 class="pmc_sec_title">Network meta-analysis</h3>
<p id="Par52">To further compare the Evolocumab and Alirocumab groups, a network meta-analysis was conducted. The network plot for LDL-C levels across different interventions is illustrated in Fig. <a href="#Fig7" class="usa-link">7</a> A, with three studies comparing Alirocumab to placebo and four studies comparing Evolocumab to placebo. There were no studies that directly compared Evolocumab to Alirocumab. The network plot for MACE across different interventions is presented in Fig. <a href="#Fig7" class="usa-link">7</a>B, with two studies comparing Alirocumab to placebo and three studies comparing Evolocumab to placebo, again without direct comparisons between the two.</p>
<figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/d296023d008b/12872_2025_5070_Fig7_HTML.jpg" loading="lazy" id="MO7" height="265" width="791" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The network plot for LDL-C levels (<strong>A</strong>) and MACE (<strong>B</strong>)</p></figcaption></figure><p id="Par53">In the LDL-C analysis, no significant findings were observed in the inconsistency tests, and consistency analysis was performed. The SUCRA curve assessing the effectiveness of different interventions in lowering LDL-C is shown in Fig. <a href="#Fig8" class="usa-link">8</a>A, demonstrating that Evolocumab has the highest probability of achieving optimal LDL-C reduction. The pairwise comparison forest plot for LDL-C levels among the various interventions is displayed in Fig. <a href="#Fig8" class="usa-link">8</a>B. The LDL-C reduction following Evolocumab intervention was greater than that following Alirocumab, although the difference was not statistically significant (MD = −0.25, 95% CI: −0.82, 0.32).</p>
<figure class="fig xbox font-sm" id="Fig8"><h4 class="obj_head">Fig. 8.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/5424a024c95e/12872_2025_5070_Fig8_HTML.jpg" loading="lazy" id="MO8" height="280" width="797" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Network Meta-Analysis Results for LDL-C Indicators <strong>A</strong>: SUCRA Plot for Alirocumab, Evolocumab, and Placebo; <strong>B</strong>: airwise Comparison Forest Plotfor treatment effect comparison among Alirocumab, Evolocumab, and Placebo</p></figcaption></figure><p id="Par55">For the MACE outcomes, no significant findings were noted in the inconsistency tests, and consistency analysis was conducted. The SUCRA curve evaluating the effectiveness of different interventions in reducing MACE is illustrated in Fig. <a href="#Fig9" class="usa-link">9</a>A, indicating that Alirocumab has the highest likelihood of achieving the lowest MACE incidence. The pairwise comparison forest plot for MACE among the various interventions is displayed in Fig. <a href="#Fig9" class="usa-link">9</a>B. The risk of MACE following Alirocumab intervention was lower than that following Evolocumab, but this difference was not statistically significant (OR = 1.03, 95% CI: 0.54, 1.97).</p>
<figure class="fig xbox font-sm" id="Fig9"><h4 class="obj_head">Fig. 9.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374482_12872_2025_5070_Fig9_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/9e1c2c5c7602/12872_2025_5070_Fig9_HTML.jpg" loading="lazy" id="MO9" height="279" width="797" alt="Fig. 9"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig9/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Network Meta-Analysis Results for MACE Indicators <strong>A</strong>: SUCRA Plot for Alirocumab, Evolocumab, and Placebo; <strong>B</strong>: Pairwise Comparison Forest Plot for treatment effect comparison among Alirocumab, Evolocumab, and Placebo</p></figcaption></figure></section><section id="Sec23"><h3 class="pmc_sec_title">GRADE summary of findings</h3>
<p id="Par56">Based on these studies, the customized GRADE summary of findings is presented in Table <a href="#Tab3" class="usa-link">3</a>, which focused on LDL-C reduction and MACE.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>PCSK9 inhibitors vs. Placebo/Statin in acute coronary syndrome </p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Outcome</th>
<th align="left" colspan="1" rowspan="1">Comparison</th>
<th align="left" colspan="1" rowspan="1">Effect Estimate (95% CI)</th>
<th align="left" colspan="1" rowspan="1">Certainty of Evidence (GRADE)</th>
<th align="left" colspan="1" rowspan="1">Reasons for Downgrading/Upgrading</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>LDL-C reduction (mg/dL)</strong>
</td>
<td align="left" colspan="1" rowspan="1">Evolocumab vs. Placebo</td>
<td align="left" colspan="1" rowspan="1">MD − 55.4 (–65.1 to − 45.7)</td>
<td align="left" colspan="1" rowspan="1">
<strong>High</strong>
</td>
<td align="left" colspan="1" rowspan="1">Consistent results across GLAGOV [18], EVOPACS [15], and others</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Alirocumab vs. Placebo</td>
<td align="left" colspan="1" rowspan="1">MD − 49.1 (–58.3 to − 39.9)</td>
<td align="left" colspan="1" rowspan="1">
<strong>High</strong>
</td>
<td align="left" colspan="1" rowspan="1">Strong effects, minimal heterogeneity, PACMAN-AMI [22], ODYSSEY [19]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Evolocumab vs. Statin alone</td>
<td align="left" colspan="1" rowspan="1">MD − 27.8 (–34.5 to − 21.1)</td>
<td align="left" colspan="1" rowspan="1">
<strong>Moderate</strong>
</td>
<td align="left" colspan="1" rowspan="1">Downgraded for indirectness (statin regimens varied)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<strong>MACE incidence</strong>
</td>
<td align="left" colspan="1" rowspan="1">Evolocumab vs. Placebo</td>
<td align="left" colspan="1" rowspan="1">OR 0.79 (0.68 to 0.92)</td>
<td align="left" colspan="1" rowspan="1">
<strong>Moderate</strong>
</td>
<td align="left" colspan="1" rowspan="1">Downgraded for imprecision in early-phase trials [14][16][17]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Alirocumab vs. Placebo</td>
<td align="left" colspan="1" rowspan="1">OR 0.85 (0.74 to 0.97)</td>
<td align="left" colspan="1" rowspan="1">
<strong>Moderate</strong>
</td>
<td align="left" colspan="1" rowspan="1">Downgraded for inconsistency (e.g., PACMAN-AMI vs. ODYSSEY)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">PCSK9i (class) vs. Statin alone</td>
<td align="left" colspan="1" rowspan="1">OR 0.84 (0.72 to 0.98)</td>
<td align="left" colspan="1" rowspan="1">
<strong>Low</strong>
</td>
<td align="left" colspan="1" rowspan="1">Downgraded for indirectness and moderate heterogeneity</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec24"><h3 class="pmc_sec_title">Meta-regression analysis</h3>
<p id="Par58">Timing of intervention (≤ 7 days) and baseline LDL-C showed significant/moderately significant associations with improved outcomes. Other variables (follow-up duration, statin use, age) were not significant predictors (Fig. <a href="#Fig10" class="usa-link">10</a>).</p>
<figure class="fig xbox font-sm" id="Fig10"><h4 class="obj_head">Fig. 10.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98a6/12374482/ce68036c9bff/12872_2025_5070_Fig10_HTML.jpg" loading="lazy" id="MO10" height="422" width="598" alt="Fig. 10"></p>
<div class="p text-right font-secondary"><a href="figure/Fig10/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Meta-Regression: Effect Modifiers of Treatment Response</p></figcaption></figure><p id="Par60">Follow-up duration was not significantly associated with MACE effect size (<em>p</em> = 0.18). Baseline LDL-C levels showed a marginally significant association with greater LDL-C reduction (<em>p</em> = 0.04), suggesting patients with higher initial LDL-C may experience greater absolute benefit.</p>
<p id="Par61">Timing of intervention (within 7 days of ACS) was associated with greater MACE reduction (β = − 0.26; 95% CI: − 0.51 to − 0.01; <em>p</em> = 0.045), indicating early initiation may yield improved outcomes. No significant associations were found for mean age, sex distribution, or statin use proportion. These results suggest that while treatment effects were generally consistent, early initiation and higher baseline LDL-C may be effect modifiers warranting further investigation.</p></section></section><section id="Sec25"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par62">This systematic review and network meta-analysis evaluated the comparative efficacy of PCSK9 inhibitors, specifically Alirocumab and Evolocumab, in patients with acute myocardial infarction (AMI) and ACS. Our findings support their role in significantly reducing LDL-C levels and the risk of MACE. While Evolocumab demonstrated a stronger effect on LDL-C lowering, Alirocumab showed a slightly greater, though statistically non-significant, trend toward reducing MACE. These results are consistent with the physiological understanding of PCSK9 inhibition and expand on prior clinical evidence.</p>
<p id="Par63">The LDL-C–lowering effects we observed align with findings from a previous meta-analysis [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>], which reported reductions of nearly 50% in patients with ASCVD. Likewise, our MACE findings support evidence from the ODYSSEY OUTCOMES and FOURIER trials. For example, Schwartz et al. [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>] demonstrated that Alirocumab reduced recurrent ischemic events, particularly in high-risk patients post-ACS, a benefit echoed in our network estimates.</p>
<p id="Par64">Moreover, recent real-world analyses [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>] have demonstrated that early initiation of PCSK9 inhibitors post-AMI leads to improved outcomes, reinforcing our meta-regression result showing that early initiation (≤ 7 days) was significantly associated with greater MACE reduction (β = − 0.26; 95% CI: − 0.51 to − 0.01). However, inconsistencies in the literature remain. A pharmacological review [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>] highlighted differences in pleiotropic effects between Alirocumab and Evolocumab, potentially explaining why Alirocumab may show more pronounced benefits in mortality reduction.</p>
<p id="Par65">PCSK9 inhibitors exert their primary action by preventing LDL receptor degradation, thereby enhancing hepatic clearance of LDL-C. During ACS, PCSK9 levels acutely rise in response to inflammatory cytokines and myocardial injury. This upregulation may blunt statin efficacy, making adjunctive PCSK9 inhibition particularly valuable. Emerging research [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>] has also implicated PCSK9 in endothelial dysfunction and plaque instability, offering mechanistic support for the observed reductions in non-fatal MI and coronary revascularization.</p>
<p id="Par66">The analysis revealed high heterogeneity in LDL-C reduction (I² = 97.9%). This is likely attributable to: differences in baseline LDL-C levels, timing and duration of drug administration (ranging from single-dose to 1 year), variability in background statin and ezetimibe use, population differences (primary vs. secondary prevention cohorts, PCI vs. medical management). Subgroup and sensitivity analyses confirmed that baseline LDL-C and timing of intervention were major contributors to variability. Notably, trials using ezetimibe as background therapy (Hao Y [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]) may have enhanced LDL-C reduction and confounded treatment effect sizes.</p>
<p id="Par67">Our findings underscore the utility of PCSK9 inhibitors in secondary prevention, especially among high-risk populations—defined here as patients with prior MI, elevated baseline LDL-C, or recurrent ischemic events despite statins. The rapid onset of LDL-C lowering, particularly with early post-AMI administration, supports their use in acute settings. However, cost-effectiveness and patient selection (e.g., statin-intolerant, residual risk) remain critical considerations for routine implementation.</p>
<p id="Par68">In real-world practice, clinicians should tailor therapy based on individual risk profiles and lipid thresholds. Our SUCRA ranking suggests Evolocumab may be optimal for patients requiring rapid and profound LDL-C reduction, while Alirocumab might be considered for broader cardioprotective benefits.</p>
<p id="Par69">Although this meta-analysis focused on ACS, PCSK9 inhibitors have shown promise in other cardiovascular settings, including stroke prevention, peripheral artery disease, and diabetic cardiovascular risk [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Future pooled analyses should expand the evaluation of PCSK9 inhibition beyond coronary events to these broader indications.</p>
<p id="Par70">In comparison to published meta-analyses, the findings of this study align with multiple prior investigations. One meta-analysis demonstrated that PCSK9 inhibitors significantly reduced LDL-C levels by 49.26% in patients with atherosclerotic cardiovascular disease (ASCVD) and decreased the risk of myocardial infarction (RR = 0.73), although they did not significantly reduce the risk of cardiovascular mortality (RR = 0.97). The magnitude of LDL-C reduction observed in this study is consistent with those reported above, further elucidating the differences between Evolocumab and Alirocumab concerning MACE risk. A meta-analysis by Bodapati et al. [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>] explored the relationship between PCSK9 inhibitors and cardiovascular outcomes, indicating that Alirocumab was associated with reduced all-cause mortality risk but not Evolocumab. Both Evolocumab and Alirocumab were found to significantly lower the risks of MI, coronary revascularization, and ischemic stroke [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>], yet no comparisons were made between the two.</p>
<p id="Par71">Despite both Evolocumab and Alirocumab demonstrating significant effects in lowering LDL-C and the risk of cardiovascular events, some clinical differences remain. This study found that the superiority of Evolocumab and Alirocumab in reducing LDL-C and MACE is not consistent. Research indicates that plasma PCSK9 levels increase during acute myocardial infarction, with elevated LDL-C being one of the most critical risk factors for atherosclerosis; however, the impact of PCSK-9 variants on MI is significantly greater than its effect on LDL-C levels [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>].</p>
<p id="Par72">However, this study is not without limitations. First, the heterogeneity among the included studies somewhat affects the precision of the results. Variations in baseline patient characteristics, dosage regimens, treatment duration, concomitant medications, and study design and implementation methods may contribute to inconsistencies in the findings. Second, some studies had relatively small sample sizes and insufficient follow-up durations, which may limit the comprehensive assessment of the long-term efficacy and safety of Evolocumab, thus increasing the uncertainty of the results. Third, some studies lacked direct comparisons between Alirocumab and Evolocumab, requiring indirect inference via network modeling. Time-to-event data (HRs) were inconsistently reported, limiting our ability to fully adjust for follow-up duration. The use of ezetimibe was inconsistently documented and not excluded in all studies, potentially introducing a confounding lipid-lowering effect. Four, generalizability is limited due to exclusion of non-English literature and the predominance of high-income country trials.</p>
<p id="Par73">In the future, we should conduct head-to-head trials of Evolocumab vs. Alirocumab in post-ACS populations, evaluate early in-hospital initiation vs. delayed therapy strategies, assess cost-effectiveness and adherence in real-world settings, explore mechanistic pathways beyond lipid-lowering (e.g., anti-inflammatory or plaque-stabilizing effects), investigate PCSK9 inhibition in patients with multimorbidity or chronic kidney disease, who are often underrepresented in trials.</p></section><section id="Sec26"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par74">PCSK9 inhibitors can improve lipid profiles and reduce MACE risk in patients following myocardial infarction, acute coronary syndrome, and percutaneous coronary intervention, suggesting their potential to play a more significant role in the secondary prevention of cardiovascular disease.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Guoying Kao and Chuan Chen carried out the study concepts and design, participated in experimental studies, data analysis, statistical analysis. Ying Zhang, and Guoying Kao carried out the definition of intellectual content, data acquisition and literature research. Guoying Kao and Ying Zhang participated in clinical studies and experimental studies. Guoying Kao, Chuan Chen and Ying Zhang participated in data acquisition and analysis. Yi Xu and Gang Xu helped to clinical studies and drafted the manuscript. All authors read and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This study was supported by Chongqing Science and Health Joint Medical Research Project, approval number 2023MSXM081 and 2023 key Disciplines On Public Health Construction in Chongqing.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The simulation experiment data used to support the findings of this study are available from the corresponding author upon request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par75">This meta-analysis was approved by the institutional review board, the need for informed patient consent for inclusion was waived.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent to publish</h3>
<p id="Par76">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par77">The authors declare no competing interests.</p></section><section id="FPar4"><h3 class="pmc_sec_title">Clinical trial number</h3>
<p id="Par78">Not applicable.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Guoying Kao and Chuan Chen contributed as the co-first author.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Yi Xu, Email: XuYichongqing@163.com.</p>
<p>Gang Xu, Email: XUGANG080926@163.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327:662–75.
</cite> [<a href="https://doi.org/10.1001/jama.2022.0358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35166796/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bhatt%20DL,%20Lopes%20RD,%20Harrington%20RA.%20Diagnosis%20and%20treatment%20of%20acute%20coronary%20syndromes:%20a%20review.%20JAMA.%202022;327:662%E2%80%9375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720–826.37622654
</cite> [<a href="https://scholar.google.com/scholar_lookup?Byrne%20RA,%20Rossello%20X,%20Coughlan%20JJ,%20Barbato%20E,%20Berry%20C,%20Chieffo%20A,%20Claeys%20MJ,%20Dan%20GA,%20Dweck%20MR,%20Galbraith%20M,%20Gilard%20M,%20Hinterbuchner%20L,%20Jankowska%20EA,%20J%C3%BCni%20P,%20Kimura%20T,%20Kunadian%20V,%20Leosdottir%20M,%20Lorusso%20R,%20Pedretti%20RFE,%20Rigopoulos%20AG,%20Rubini%20Gimenez%20M,%20Thiele%20H,%20Vranckx%20P,%20Wassmann%20S,%20Wenger%20NK,%20Ibanez%20B.%202023%20ESC%20guidelines%20for%20the%20management%20of%20acute%20coronary%20syndromes.%20Eur%20Heart%20J.%202023;44:3720%E2%80%93826.37622654" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Wilkinson MJ, Lepor NE, Michos ED. Evolving management of Low-Density lipoprotein cholesterol: A personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12:e028892.
</cite> [<a href="https://doi.org/10.1161/JAHA.122.028892" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10381990/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37260036/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wilkinson%20MJ,%20Lepor%20NE,%20Michos%20ED.%20Evolving%20management%20of%20Low-Density%20lipoprotein%20cholesterol:%20A%20personalized%20approach%20to%20preventing%20atherosclerotic%20cardiovascular%20disease%20across%20the%20risk%20continuum.%20J%20Am%20Heart%20Assoc.%202023;12:e028892." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Stein EA, Raal FJ. Lipid-lowering drug therapy for CVD prevention: looking into the future. Curr Cardiol Rep. 2015;17:104.
</cite> [<a href="https://doi.org/10.1007/s11886-015-0659-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26385394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Stein%20EA,%20Raal%20FJ.%20Lipid-lowering%20drug%20therapy%20for%20CVD%20prevention:%20looking%20into%20the%20future.%20Curr%20Cardiol%20Rep.%202015;17:104." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Hajar R. PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views. 2019;20:74–5.
</cite> [<a href="https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_59_19" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6686613/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hajar%20R.%20PCSK%209%20inhibitors:%20a%20short%20history%20and%20a%20new%20era%20of%20lipid-lowering%20therapy.%20Heart%20Views.%202019;20:74%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Poirier S, Mayer GJDD. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013;7:1135–48.
</cite> [<a href="https://doi.org/10.2147/DDDT.S36984" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3793591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24115837/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Poirier%20S,%20Mayer%20GJDD.%20The%20biology%20of%20PCSK9%20from%20the%20endoplasmic%20reticulum%20to%20lysosomes:%20new%20and%20emerging%20therapeutics%20to%20control%20low-density%20lipoprotein%20cholesterol.%20Drug%20Des%20Devel%20Ther.%202013;7:1135%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>McDonagh M, Peterson K, Holzhammer B, Fazio S. A systematic review of PCSK9 inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm. 2016;22:641–q53.
</cite> [<a href="https://doi.org/10.18553/jmcp.2016.22.6.641" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10397903/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27231792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McDonagh%20M,%20Peterson%20K,%20Holzhammer%20B,%20Fazio%20S.%20A%20systematic%20review%20of%20PCSK9%20inhibitors%20Alirocumab%20and%20Evolocumab.%20J%20Manag%20Care%20Spec%20Pharm.%202016;22:641%E2%80%93q53." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Schwartz GG, Steg G, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema WJ, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD. Zeiher AMJTNEJoM. Alirocumab Cardiovasc Outcomes after Acute Coron Syndrome. 2018;379:2097–107.</cite> [<a href="https://scholar.google.com/scholar_lookup?Schwartz%20GG,%20Steg%20G,%20Szarek%20M,%20Bhatt%20DL,%20Bittner%20VA,%20Diaz%20R,%20Edelberg%20JM,%20Goodman%20SG,%20Hanotin%20C,%20Harrington%20RA,%20Jukema%20WJ,%20Lecorps%20G,%20Mahaffey%20KW,%20Moryusef%20A,%20Pordy%20R,%20Quintero%20K,%20Roe%20MT,%20Sasiela%20WJ,%20Tamby%20JF,%20Tricoci%20P,%20White%20HD.%20Zeiher%20AMJTNEJoM.%20Alirocumab%20Cardiovasc%20Outcomes%20after%20Acute%20Coron%20Syndrome.%202018;379:2097%E2%80%93107." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagström E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, Simon T, Steg PG. Alirocumab and cardiovascular outcomes in patients with previous myocardial infarction: prespecified subanalysis from ODYSSEY OUTCOMES. Can J Cardiol. 2022;38:1542–9.
</cite> [<a href="https://doi.org/10.1016/j.cjca.2022.05.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35644332/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chiang%20CE,%20Schwartz%20GG,%20Elbez%20Y,%20Szarek%20M,%20Bhatt%20DL,%20Bittner%20VA,%20Diaz%20R,%20Erglis%20A,%20Goodman%20SG,%20Hagstr%C3%B6m%20E,%20Jukema%20JW,%20Liberopoulos%20E,%20Loy%20M,%20Pordy%20R,%20White%20HD,%20Simon%20T,%20Steg%20PG.%20Alirocumab%20and%20cardiovascular%20outcomes%20in%20patients%20with%20previous%20myocardial%20infarction:%20prespecified%20subanalysis%20from%20ODYSSEY%20OUTCOMES.%20Can%20J%20Cardiol.%202022;38:1542%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Ignatyeva V, Kontsevaya AV, Drapkina OM, Derkach EVJKKPGCP. Drugs influencing on PCSK9 activity: modelling of efficacy in patients who had myocardial infarction with uncontrolled dyslipidemia. Good Clinical Practice. 2023;59–69. 10.37489/2588-0519-2023-2-59-69.</cite>
</li>
<li id="CR11">
<span class="label">11.</span><cite>Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lønborg J, Fahrni G, Iglesias JF, van Geuns RJM, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrøm T, Lang IM, Koskinas KCJJ. Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771–81. 10.1001/jama.2022.5218.</cite> [<a href="https://doi.org/10.1001/jama.2022.5218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8978048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35368058/" class="usa-link">PubMed</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Rexhaj E, Soria R, Baer S, Kavaliauskaite R, Yasushi U, Tatsuhiko O, Temperli F, Shibutani H, Siontis Cm G, Haener DJ, Stortecky S, Windecker S, Koskinas CK, Losdat S, Raeber LJEHJ. Effect of Alirocumab added to high-Intensity Statin therapy on endothelial function in patients with acute myocardial infarction: a sub-study of the randomized placebo-controlled PACMAN-AMI trial. European Heart J. 2022;43. 10.1093/eurheartj/ehac544.1398.</cite>
</li>
<li id="CR13">
<span class="label">13.</span><cite>Bodapati Ap, Hanif A, Okafor DK, Katyal G, Kaur G, Ashraf H, Khan SJC. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis. 2023;15.</cite> [<a href="https://doi.org/10.7759/cureus.46605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10626223/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37937036/" class="usa-link">PubMed</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15:1308–21.
</cite> [<a href="https://doi.org/10.1016/j.jcmg.2022.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35431172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nicholls%20SJ,%20Kataoka%20Y,%20Nissen%20SE,%20Prati%20F,%20Windecker%20S,%20Puri%20R,%20Hucko%20T,%20Aradi%20D,%20Herrman%20JR,%20Hermanides%20RS,%20Wang%20B,%20Wang%20H,%20Butters%20J,%20Di%20Giovanni%20G,%20Jones%20S,%20Pompili%20G,%20Psaltis%20PJ.%20Effect%20of%20evolocumab%20on%20coronary%20plaque%20phenotype%20and%20burden%20in%20statin-treated%20patients%20following%20myocardial%20infarction.%20JACC%20Cardiovasc%20Imaging.%202022;15:1308%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452–62.
</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31479722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Koskinas%20KC,%20Windecker%20S,%20Pedrazzini%20G,%20Mueller%20C,%20Cook%20S,%20Matter%20CM,%20Muller%20O,%20H%C3%A4ner%20J,%20Gencer%20B,%20Crljenica%20C,%20Amini%20P,%20Deckarm%20O,%20Iglesias%20JF,%20R%C3%A4ber%20L,%20Heg%20D,%20Mach%20F.%20Evolocumab%20for%20early%20reduction%20of%20LDL%20cholesterol%20levels%20in%20patients%20with%20acute%20coronary%20syndromes%20(EVOPACS).%20J%20Am%20Coll%20Cardiol.%202019;74:2452%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Hao Y, Yang YL, Wang YC, Li J. Effect of the early application of Evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J. 2022;63:669–77.
</cite> [<a href="https://doi.org/10.1536/ihj.22-052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35831153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hao%20Y,%20Yang%20YL,%20Wang%20YC,%20Li%20J.%20Effect%20of%20the%20early%20application%20of%20Evolocumab%20on%20blood%20lipid%20profile%20and%20cardiovascular%20prognosis%20in%20patients%20with%20extremely%20high-risk%20acute%20coronary%20syndrome.%20Int%20Heart%20J.%202022;63:669%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Furtado RHM, Fagundes AA Jr., Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Effect of evolocumab in patients with prior percutaneous coronary intervention. Circ Cardiovasc Interv. 2022;15: e011382.
</cite> [<a href="https://doi.org/10.1161/CIRCINTERVENTIONS.121.011382" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35209731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Furtado%20RHM,%20Fagundes%20AA%20Jr.,%20Oyama%20K,%20Zelniker%20TA,%20Tang%20M,%20Kuder%20JF,%20Murphy%20SA,%20Hamer%20A,%20Wang%20H,%20Keech%20AC,%20Giugliano%20RP,%20Sabatine%20MS,%20Bergmark%20BA.%20Effect%20of%20evolocumab%20in%20patients%20with%20prior%20percutaneous%20coronary%20intervention.%20Circ%20Cardiovasc%20Interv.%202022;15:%20e011382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373–84.
</cite> [<a href="https://doi.org/10.1001/jama.2016.16951" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27846344/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nicholls%20SJ,%20Puri%20R,%20Anderson%20T,%20Ballantyne%20CM,%20Cho%20L,%20Kastelein%20JJ,%20Koenig%20W,%20Somaratne%20R,%20Kassahun%20H,%20Yang%20J,%20Wasserman%20SM,%20Scott%20R,%20Ungi%20I,%20Podolec%20J,%20Ophuis%20AO,%20Cornel%20JH,%20Borgman%20M,%20Brennan%20DM,%20Nissen%20SE.%20Effect%20of%20evolocumab%20on%20progression%20of%20coronary%20disease%20in%20statin-treated%20patients:%20the%20GLAGOV%20randomized%20clinical%20trial.%20JAMA.%202016;316:2373%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1801174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30403574/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schwartz%20GG,%20Steg%20PG,%20Szarek%20M,%20Bhatt%20DL,%20Bittner%20VA,%20Diaz%20R,%20Edelberg%20JM,%20Goodman%20SG,%20Hanotin%20C,%20Harrington%20RA,%20Jukema%20JW,%20Lecorps%20G,%20Mahaffey%20KW,%20Moryusef%20A,%20Pordy%20R,%20Quintero%20K,%20Roe%20MT,%20Sasiela%20WJ,%20Tamby%20JF,%20Tricoci%20P,%20White%20HD,%20Zeiher%20AM.%20Alirocumab%20and%20cardiovascular%20outcomes%20after%20acute%20coronary%20syndrome.%20N%20Engl%20J%20Med.%202018;379:2097%E2%80%93107." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Mehta SR, Pare G, Lonn EM, Jolly SS, Natarajan MK, Pinilla-Echeverri N, Schwalm JD, Sheth TN, Sibbald M, Tsang M, Valettas N, Velianou JL, Lee SF, Ferdous T, Nauman S, Nguyen H, McCready T, McQueen MJ. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18:e888-96.
</cite> [<a href="https://doi.org/10.4244/EIJ-D-22-00735" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9743253/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36349701/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mehta%20SR,%20Pare%20G,%20Lonn%20EM,%20Jolly%20SS,%20Natarajan%20MK,%20Pinilla-Echeverri%20N,%20Schwalm%20JD,%20Sheth%20TN,%20Sibbald%20M,%20Tsang%20M,%20Valettas%20N,%20Velianou%20JL,%20Lee%20SF,%20Ferdous%20T,%20Nauman%20S,%20Nguyen%20H,%20McCready%20T,%20McQueen%20MJ.%20Effects%20of%20routine%20early%20treatment%20with%20PCSK9%20inhibitors%20in%20patients%20undergoing%20primary%20percutaneous%20coronary%20intervention%20for%20ST-segment%20elevation%20myocardial%20infarction:%20a%20randomised,%20double-blind,%20sham-controlled%20trial.%20EuroIntervention.%202022;18:e888-96." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, Schindler TH, Latina J, Schulman SP, Gerstenblith G. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142:419–21.
</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.120.046320" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8323059/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32718248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Leucker%20TM,%20Blaha%20MJ,%20Jones%20SR,%20Vavuranakis%20MA,%20Williams%20MS,%20Lai%20H,%20Schindler%20TH,%20Latina%20J,%20Schulman%20SP,%20Gerstenblith%20G.%20Effect%20of%20evolocumab%20on%20atherogenic%20lipoproteins%20during%20the%20peri-%20and%20early%20postinfarction%20period:%20a%20placebo-controlled,%20randomized%20trial.%20Circulation.%202020;142:419%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrøm T, Lang IM, Koskinas KC. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771–81.
</cite> [<a href="https://doi.org/10.1001/jama.2022.5218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8978048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35368058/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?R%C3%A4ber%20L,%20Ueki%20Y,%20Otsuka%20T,%20Losdat%20S,%20H%C3%A4ner%20JD,%20Lonborg%20J,%20Fahrni%20G,%20Iglesias%20JF,%20van%20Geuns%20RJ,%20Ondracek%20AS,%20Radu%20Juul%20Jensen%20MD,%20Zanchin%20C,%20Stortecky%20S,%20Spirk%20D,%20Siontis%20GCM,%20Saleh%20L,%20Matter%20CM,%20Daemen%20J,%20Mach%20F,%20Heg%20D,%20Windecker%20S,%20Engstr%C3%B8m%20T,%20Lang%20IM,%20Koskinas%20KC.%20Effect%20of%20alirocumab%20added%20to%20high-intensity%20statin%20therapy%20on%20coronary%20atherosclerosis%20in%20patients%20with%20acute%20myocardial%20infarction:%20the%20PACMAN-AMI%20randomized%20clinical%20trial.%20JAMA.%202022;327:1771%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Marfella R, Prattichizzo F, Sardu C, Paolisso P, D’Onofrio N, Scisciola L, La Grotta R, Frigé C, Ferraraccio F, Panarese I, Fanelli M, Modugno P, Calafiore AM, Melchionna M, Sasso FC, Furbatto F, D’Andrea D, Siniscalchi M, Mauro C, Cesaro A, Calabrò P, Santulli G, Balestrieri ML, Barbato E, Ceriello A, Paolisso G. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378:117180.
</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2023.06.971" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37422356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marfella%20R,%20Prattichizzo%20F,%20Sardu%20C,%20Paolisso%20P,%20D%E2%80%99Onofrio%20N,%20Scisciola%20L,%20La%20Grotta%20R,%20Frig%C3%A9%20C,%20Ferraraccio%20F,%20Panarese%20I,%20Fanelli%20M,%20Modugno%20P,%20Calafiore%20AM,%20Melchionna%20M,%20Sasso%20FC,%20Furbatto%20F,%20D%E2%80%99Andrea%20D,%20Siniscalchi%20M,%20Mauro%20C,%20Cesaro%20A,%20Calabr%C3%B2%20P,%20Santulli%20G,%20Balestrieri%20ML,%20Barbato%20E,%20Ceriello%20A,%20Paolisso%20G.%20Evidence%20of%20an%20anti-inflammatory%20effect%20of%20PCSK9%20inhibitors%20within%20the%20human%20atherosclerotic%20plaque.%20Atherosclerosis.%202023;378:117180." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Laufs U, De Caterina R, Schiele F, Sionis A, Zaman A, Catapano AL, ACS EuroPath Trained Group. The ACS EuroPath survey series: time trends in lipid management after an acute coronary syndrome. Eur J Prev Cardiol. 2025;1:zwaf399.</cite> [<a href="https://doi.org/10.1093/eurjpc/zwaf399" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40590247/" class="usa-link">PubMed</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Ferri N, Ruscica M, Lupo MG, Vicenzi M, Sirtori CR, Corsini A. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9. Pharmacol Res. 2022;184: 106439.
</cite> [<a href="https://doi.org/10.1016/j.phrs.2022.106439" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36100012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ferri%20N,%20Ruscica%20M,%20Lupo%20MG,%20Vicenzi%20M,%20Sirtori%20CR,%20Corsini%20A.%20Pharmacological%20rationale%20for%20the%20very%20early%20treatment%20of%20acute%20coronary%20syndrome%20with%20monoclonal%20antibodies%20anti-PCSK9.%20Pharmacol%20Res.%202022;184:%20106439." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Yamashita S, Sakamoto A, Shoji S, Kawaguchi Y, Wakabayashi Y, Matsunaga M, Suguro K, Matsumoto Y, Takase H, Onodera T, Tawarahara K, Muto M, Shirasaki Y, Katoh H, Sano M, Suwa K, Naruse Y, Ohtani H, Saotome M, Urushida T, Kohsaka S, Okada E, Maekawa Y. Feasibility of short-term aggressive lipid-lowering therapy with the PCSK9 antibody in acute coronary syndrome. J Cardiovasc Dev Dis. 2023;10(5):204.
</cite> [<a href="https://doi.org/10.3390/jcdd10050204" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10219227/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37233171/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yamashita%20S,%20Sakamoto%20A,%20Shoji%20S,%20Kawaguchi%20Y,%20Wakabayashi%20Y,%20Matsunaga%20M,%20Suguro%20K,%20Matsumoto%20Y,%20Takase%20H,%20Onodera%20T,%20Tawarahara%20K,%20Muto%20M,%20Shirasaki%20Y,%20Katoh%20H,%20Sano%20M,%20Suwa%20K,%20Naruse%20Y,%20Ohtani%20H,%20Saotome%20M,%20Urushida%20T,%20Kohsaka%20S,%20Okada%20E,%20Maekawa%20Y.%20Feasibility%20of%20short-term%20aggressive%20lipid-lowering%20therapy%20with%20the%20PCSK9%20antibody%20in%20acute%20coronary%20syndrome.%20J%20Cardiovasc%20Dev%20Dis.%202023;10(5):204." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Santulli G, Kansakar U, Jankauskas SS, Varzideh F, Comparative LDL-C. Lowering efficacy of Non-Statin therapies: inclisiran is better than ezetimibe, PCSK9 inhibitors, and bempedoic acid. J Cardiovasc Pharmacol. 2025 Jun;25. 10.1097/FJC.0000000000001731.</cite> [<a href="https://doi.org/10.1097/FJC.0000000000001731" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40560167/" class="usa-link">PubMed</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, -van der Maitland AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572–80.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(12)60312-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3419820/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22607825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Voight%20BF,%20Peloso%20GM,%20Orho-Melander%20M,%20Frikke-Schmidt%20R,%20Barbalic%20M,%20Jensen%20MK,%20Hindy%20G,%20H%C3%B3lm%20H,%20Ding%20EL,%20Johnson%20T,%20Schunkert%20H,%20Samani%20NJ,%20Clarke%20R,%20Hopewell%20JC,%20Thompson%20JF,%20Li%20M,%20Thorleifsson%20G,%20Newton-Cheh%20C,%20Musunuru%20K,%20Pirruccello%20JP,%20Saleheen%20D,%20Chen%20L,%20Stewart%20A,%20Schillert%20A,%20Thorsteinsdottir%20U,%20Thorgeirsson%20G,%20Anand%20S,%20Engert%20JC,%20Morgan%20T,%20Spertus%20J,%20Stoll%20M,%20Berger%20K,%20Martinelli%20N,%20Girelli%20D,%20McKeown%20PP,%20Patterson%20CC,%20Epstein%20SE,%20Devaney%20J,%20Burnett%20MS,%20Mooser%20V,%20Ripatti%20S,%20Surakka%20I,%20Nieminen%20MS,%20Sinisalo%20J,%20Lokki%20ML,%20Perola%20M,%20Havulinna%20A,%20de%20Faire%20U,%20Gigante%20B,%20Ingelsson%20E,%20Zeller%20T,%20Wild%20P,%20de%20Bakker%20PI,%20Klungel%20OH,%20-van%20der%20Maitland%20AH,%20Peters%20BJ,%20de%20Boer%20A,%20Grobbee%20DE,%20Kamphuisen%20PW,%20Deneer%20VH,%20Elbers%20CC,%20Onland-Moret%20NC,%20Hofker%20MH,%20Wijmenga%20C,%20Verschuren%20WM,%20Boer%20JM,%20van%20der%20Schouw%20YT,%20Rasheed%20A,%20Frossard%20P,%20Demissie%20S,%20Willer%20C,%20Do%20R,%20Ordovas%20JM,%20Abecasis%20GR,%20Boehnke%20M,%20Mohlke%20KL,%20Daly%20MJ,%20Guiducci%20C,%20Burtt%20NP,%20Surti%20A,%20Gonzalez%20E,%20Purcell%20S,%20Gabriel%20S,%20Marrugat%20J,%20Peden%20J,%20Erdmann%20J,%20Diemert%20P,%20Willenborg%20C,%20K%C3%B6nig%20IR,%20Fischer%20M,%20Hengstenberg%20C,%20Ziegler%20A,%20Buysschaert%20I,%20Lambrechts%20D,%20Van%20de%20Werf%20F,%20Fox%20KA,%20El%20Mokhtari%20NE,%20Rubin%20D,%20Schrezenmeir%20J,%20Schreiber%20S,%20Sch%C3%A4fer%20A,%20Danesh%20J,%20Blankenberg%20S,%20Roberts%20R,%20McPherson%20R,%20Watkins%20H,%20Hall%20AS,%20Overvad%20K,%20Rimm%20E,%20Boerwinkle%20E,%20Tybjaerg-Hansen%20A,%20Cupples%20LA,%20Reilly%20MP,%20Melander%20O,%20Mannucci%20PM,%20Ardissino%20D,%20Siscovick%20D,%20Elosua%20R,%20Stefansson%20K,%20O%E2%80%99Donnell%20CJ,%20Salomaa%20V,%20Rader%20DJ,%20Peltonen%20L,%20Schwartz%20SM,%20Altshuler%20D,%20Kathiresan%20S.%20Plasma%20HDL%20cholesterol%20and%20risk%20of%20myocardial%20infarction:%20a%20Mendelian%20randomisation%20study.%20Lancet.%202012;380:572%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The simulation experiment data used to support the findings of this study are available from the corresponding author upon request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Cardiovascular Disorders are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12872-025-05070-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12872_2025_Article_5070.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.7 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374482/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374482/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374482%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374482/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374482/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374482/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40849610/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374482/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40849610/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374482/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374482/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Qy4d7IqndGIw7H0QEcq2MRFDzT6znxiTrmGMaoQwaiTp4TYqcg00gWUVlxKCZGs2">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
